Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 06 September 2013 | By Alexander Gaffney, RAC,
Fallout from deficient findings at a contract testing laboratory used by dozens of pharmaceutical compounders continues to upend the compounding industry, with yet another company initiating a nationwide recall after it said it was unable to confirm whether its products are indeed sterile.
In August 2013, the US Food and Drug Administration issued a statement that Loveland, CO-based Front Range Laboratories, Inc. had been observed to be using deficient methods to assess the sterility, strength and stability of products brought to it for testing.
"FDA has concerns that results obtained from Front Range are not reliable," FDA said in a statement. "FDA recommends that pharmacies not use this firm for sterility and other quality attributes testing at this time."
Unlike previous inspections of compounding facilities by FDA, which generally focused on just a single company's products, Front Range's activities potentially affected more than 100 pharmacies across 32 US states, whose products could likely be found in all 50 states.
By 28 August 2013, FDA had announced the recall of products by three companies who had contracted with Front Range for Testing: Park Pharmacy & Compounding Center; Wellness Pharmacy, Inc; and JCB Laboratories.
"This recall was initiated after Wellness Pharmacy was notified that in a recent inspection of Front Range Labs … may have resulted in Wellness Pharmacy receiving inaccurate sterility test results on these lots," one of the companies, Wellness Pharmacy, wrote in its recall statement. "FDA has concerns that test results obtained from Front Range Labs may not be reliable."
The one piece of positive news from the recalls may have been their limited scope. Unlike some previous recalls, which affected dozens of products distributed over a lengthy period of time, the three recalls combined affected just 14 lots of product.
Now FDA is confirming that a fourth company, Medaus Pharmacy of Birmingham, AL, has been affected due to deficient third-party testing.
"Medaus Pharmacy is voluntarily recalling certain sterile compounded consumer products due to inability to confirm that the quality control testing performed on these specific lots by an independent, third party laboratory was conducted in a manner consistent with standards," the company said in a statement. "Though Medaus received test results indicating that these lots met all safety standards, they are being recalled because the independent testing lab's sterility testing practices as applied to these lots indicate that the product's sterility cannot be confirmed."
The company said that while it was unaware of any specific adverse events associated with its product, sterility lapses could hypothetically expose patients to serious life-threatening infections. Ten lots of eight different products are included in the recall.
The description of the lapses closely matches the account of Front Range, though the statement does not mention the company by name. Attempts to reach Medaus for comment were unsuccessful.
We've reached out to FDA for comment on whether the recall is related to Front Range or an as-yet-unknown second testing facility.
FDA Recall Notice
Medaus Recall Notice
Tags: Pharmaceutical Compounding, Recall
Regulatory Focus newsletters
All the biggest regulatory news and happenings.